EKF Diagnostics Holdings PLC on Monday said it anticipates revenue and earnings gains for its full-year, as it noted flat interim revenue for the first half of 2025.
The Cardiff-headquartered medical diagnostics company said revenue in the six that ended June 30 was £25.2 million, flat with the year before and in line with management expectations.
Gross margins improved to 50% from 48%, said EKF Diagnostics, with adjusted earnings before interest, tax, depreciation and amortisation showing ‘continued growth’.
At constant currency, EKF Diagnostics said that revenue and adjusted Ebitda rose by 2% and 9% respectively.
It added that its five-year plan is continuing in line with management expectations, noting a strong revenue performance in the key growth areas of Hematology, up 8% on-year, and beta-HB, up 12%.
Back in March at its full-year results, EKF Diagnostics outlined a five-year strategic development plan to deliver revenue growth and improved profitability across all of its divisions.
Looking to the full-year, it said it remains on track to achieve revenue and adjusted Ebitda in line with market expectations of £56.3 million and £12.3 million respectively. These are up 12% and 9.7% from £50.2 million and £11.3 million in 2024.
The company is set to report its half-year numbers on September 16.
Shares in EKF Diagnostics edged 3.4% higher to 27.40 pence on Monday afternoon in London.
Copyright 2025 Alliance News Ltd. All Rights Reserved.
